World Cancer Day, 4 February 2024

Join us in commemorating World Cancer Day on 4th February by exploring our specially curated collection of articles that delve into the multi-faceted aspects of this pervasive disease. This collection will provide you with a comprehensive overview of the latest advancements in cancer research and treatment.

Annals of Oncology

• ●

  Diversity in clinical trials in Europe and the USA: a review of a pharmaceutical company’s data collection, reporting, and interpretation of race and ethnicity - Annals of Oncology(opens in new tab/window)

• ●

  ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe☆ - Annals of Oncology(opens in new tab/window)

• ●

  European cancer mortality predictions for the year 2024 with focus on colorectal cancer(opens in new tab/window)

Cancer Letters

• ●

  Drug conjugate-based anticancer therapy - Current status and perspectives(opens in new tab/window)

• ●

  Cope with copper: From copper linked mechanisms to copper-based clinical cancer therapies(opens in new tab/window)

Current Problems in Cancer

• ●

  Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors(opens in new tab/window)

• ●

  Innovations and Opportunities for the Integration of Palliative Care in Cancer Care(opens in new tab/window)

Current Problems in Cancer: Case Reports

• ●

  Mixed response to chemotherapy in triple-negative breast cancer: a case report(opens in new tab/window)

• ●

  A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report(opens in new tab/window)

ESMO Gastrointestinal Oncology

• ●

  ARCAD-Asia initiative: leveraging yesterday’s data for tomorrow - ESMO Gastrointestinal Oncology(opens in new tab/window)

• ●

  Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study - ESMO Open(opens in new tab/window)

ESMO Real World Data and Digital Oncology

• ●

  Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities - ESMO Real World Data and Digital Oncology (esmorwd.org)(opens in new tab/window)

European Journal of Cancer

• ●

  First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations(opens in new tab/window)

• ●

  Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network(opens in new tab/window)

Immuno-Oncology and Technology

• ●

  ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing - Immuno-Oncology and Technology (esmoiotech.org)(opens in new tab/window)

Journal of Thoracic Oncology

• ●

  LUNG CANCER WORLDWIDE COLLECTION(opens in new tab/window)

• ●

  The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors(opens in new tab/window)

• ●

  The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors(opens in new tab/window)

• ●

  The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: A Re-Assessment of the International Thymic Malignancy Interest Group/International Association for the Study of Lung Cancer Lymph Node Map for Thymic Epithelial Tumors for the Forthcoming Ninth Edition of the TNM Classification of Malignant Tumors(opens in new tab/window)

• ●

  The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors(opens in new tab/window)

• ●

  The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors(opens in new tab/window)

• ●

  IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer(opens in new tab/window)

• ●

  The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer(opens in new tab/window)

• ●

  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revisions of the T-Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer(opens in new tab/window)

• ●

  International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy(opens in new tab/window)

• ●

  Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial(opens in new tab/window)

• ●

  Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations(opens in new tab/window)

• ●

  Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer(opens in new tab/window)

• ●

  Lung Cancer Screening in Asia: An Expert Consensus Report(opens in new tab/window)

• ●

  Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer(opens in new tab/window)

• ●

  Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC(opens in new tab/window)

• ●

  Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial(opens in new tab/window)

• ●

  Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer(opens in new tab/window)

• ●

  Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation(opens in new tab/window)

• ●

  A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC(opens in new tab/window)

• ●

  Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study(opens in new tab/window)

• ●

  Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis(opens in new tab/window)

• ●

  Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib(opens in new tab/window)

• ●

  Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium(opens in new tab/window)

• ●

  Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC(opens in new tab/window)

• ●

  Robotic Esophagectomy Compared With Open Esophagectomy Reduces Sarcopenia within the First Postoperative Year: A Propensity Score-Matched Analysis(opens in new tab/window)

• ●

  Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study(opens in new tab/window)

• ●

  UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)(opens in new tab/window)

JTO Clinical and Research Reports

• ●

  Health Care Utilization and Costs in Lung Cancer Screening Participants—A Propensity-Matched Economic Analysis(opens in new tab/window)

• ●

  Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience(opens in new tab/window)

• ●

  Comparison of Lung Cancer Surgery Outcomes in Queensland for Indigenous and Nonindigenous Australians(opens in new tab/window)

• ●

  Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment(opens in new tab/window)

• ●

  Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy(opens in new tab/window)

• ●

  Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC(opens in new tab/window)

• ●

  Racial, Ethnic, and Socioeconomic Characteristics Independently Predict for Cachexia Risk and Associated Survival Outcomes in Stage IV NSCLC: A Brief Report(opens in new tab/window)

Neoplasia

• ●

  The children's brain tumor network (CBTN) – Accelerating research in pediatric central nervous system tumors through collaboration and open science(opens in new tab/window)

• ●

  Maestros of malignancy: Microbes as the conductors of carcinogenesis(opens in new tab/window)